

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 14 January 2026. At the meeting 10 977 485 shares were represented, which corresponds to approx. 36 percent of the total number of shares. The summary below shows the resolutions adopted at the AGM. The resolutions were adopted unanimously.

Allocation of the company's result

The AGM resolved to adopt the income statement and balance sheet for the company as well as the consolidated income statement and consolidated balance sheet for the previous financial year. The board of directors and the managing director were discharged from liability for the same period.

The AGM approved the board's proposal that the result should be carried forward.

Fees to the board members and the auditors

The AGM agreed on the following fees to the board and the auditors.

Remuneration to non-employed board members elected by a general meeting shall be paid in the amount of SEK 150,000 to the chairman of the board and SEK 75,000 to each of the other board members.

Fees to the auditors shall be paid in accordance with approved invoices.

Board members, chairman of the board and auditors

The AGM agreed that the Board of Directors shall consist of five members without deputies. The AGM re-elected Karl Karlsson, Johan Strömqvist, Ramon Vila and Ivailo S. Georgiev as Board members. Johan Orvelin was elected as new Board member. Andreas Hedskog and Anil Okay were not re-elected. Ivailo S. Georgiev was re-elected as Chairman of the Board.

Ernst & Young AB was elected as the company's auditor, with Martin Henriksson as auditor in charge.

Authorization for the board to decide on issue of new shares

The AGM resolved to authorize the board of Newbury Pharmaceuticals AB to decide to issue new shares in the company, in accordance with the board's proposal.

Press Release
14 January 2026 11:15:00 CET



For more information, contact:

Karl Karlsson, CEO
karl.karlsson@newburypharma.com
Mobile: +46 46 12 11 20

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB](#)